Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Best of ASCO® Miami 2016 /
'Other' targets in lung cancer

8th - 10th Jul 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.07.16
Views: 1572
Rating:

Dr Edward Garon - David Geffen School of Medicine at the University of California, Los Angeles, USA

Dr Garon speaks with ecancertv at the Best of ASCO 2016 about targetable mutations in lung cancer.

With examples of BRAF and RET mutations, he discusses the clinical significance of sequencing data in achieving a patient's best possible responses to therapy.

For more on lung cancer sequencing, watch Dr Bruce Johnson speaking to ecancertv at WIN 2016.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation